Agenda set for upcoming global conference on stem cell therapy to be held Jan. 20-21, 2011
WHAT:
The agenda for the Sixth International Conference on Cell Therapy for Cardiovascular Disease (IC3D) has been set and is available at http://celltherapy.crf.org/conference/agenda.html. The conference, which will be held January 20-21, 2011, is a one-and-a-half day comprehensive program dedicated to the evolving field of cell-based therapies for the repair and regeneration of cardiac and vascular disease, as well as related diseases such as diabetes and stroke. This year's conference will focus on commercialization aspects of the field, highlighting the status of molecular, cell, and tissue products in addition to delivery systems.
WHY:
Now in its 10th year of clinical trials, the application of stem cells in the treatment of cardiovascular diseases has seen many notable successes, as well as identified challenges that await the next round of clinical studies. Leaders in the field will convene to present their work, experiences, observations, and opinions on the benefits and unmet challenges of cell-based therapies.
Sessions will focus on:
- Autologous cell products
- Allogenic cells, hybrid preparations, and specialty products
- Molecular interventions: Macro and micro agents
- Delivery methods and imaging
- Selection of biologics and methodologies in the development of the next generation of clinical trials
Warren Sherman, MD, Course Director, is Director of Cardiac Cell-Based Endovascular Therapies at the Center for Interventional Vascular Therapy at NewYork-Presbyterian Hospital and Columbia University Medical Center. Dr. Sherman is a renowned clinical investigator in the field of myocardial regeneration who pioneered a technique for injecting stem cells into the heart. In Rotterdam in May 2001, he performed the first catheter-based injection of stem cells into the heart of a patient with congestive heart failure due to a previous heart attack. At Columbia University Medical Center, researchers led by Dr. Sherman are using the patient's own myoblasts -- progenitor cells found in muscle -- to repair and replace injured cardiac tissue in a process called myogenesis. Dr. Sherman collaborates in studies to improve the outcomes of cell implantation with colleagues at Columbia University Medical Center, all of whom will be presenting their research at the conference.
WHEN:
January 20-21, 2011
WHERE:
Vivian and Seymour Milstein Family Heart Center
Myrna L. Daniels Auditorium
NewYork-Presbyterian Hospital/Columbia University Medical Center
New York, NY
For more information visit: http://celltherapy.crf.org/
HOW TO REGISTER:
Media may apply for registration by emailing jromero@crf.org.
Provided by Cardiovascular Research Foundation
